BFM
ODT

Boothbay Fund Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Boothbay Fund Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-135,743
Closed -$183K – 2719
2021
Q4 		$183K Sell
135,743
-50,626
-27% -$120K ﹤0.01% 1519
2021
Q3 		$542K Sell
186,369
-44,425
-19% -$148K 0.02% 1049
2021
Q2 		$805K Buy
230,794
+74,167
+47% +$255K 0.03% 794
2021
Q1 		$536K Buy
+156,627
New +$2.96M 0.02% 912

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Boothbay Fund Management's ODT Position: Q1 2022 in Review

Boothbay Fund Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 135,743 shares — an estimated $183K sold.

Boothbay Fund Management first reported a position in ODT in Q1 2021 and held it in 4 quarters. The position peaked at $805K in Q2 2021. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Boothbay Fund Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 135,743 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $183K.
  • Boothbay Fund Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Boothbay Fund Management's Odonate Therapeutics, Inc. Common Stock position peaked at $805K in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Boothbay Fund Management's 13F filing for Q1 2022, filed 16 May 2022.